ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Surescripts Expands Innovative Prescription Accuracy Technology, Delivering Greater Impact at Scale, Improving Patient Safety and Efficiency for Care Providers

Surescripts®, the nation's leading health information network, has now expanded its innovative Sig IQ technology, first introduced for Medication History in 2022, to E-Prescribing transactions, including NewRx and both RxRenewal Requests and Responses, to continue improving patient safety and increasing clinician efficiency at scale.

Surescripts Sig IQ technology translates free-text patient directions into a quality-controlled, clinically validated format or Structured & Codified Sig (S&C Sig). This helps reduce uncertainty around prescription medication instructions, meaning prescribers can approve requests in fewer keystrokes, while also minimizing the risk of patient harm and preventing delays in patient care.

Sig IQ’s Growing Impact:

  • In 2024, Surescripts has delivered 4.1 billion S&C Sigs in Medication History transactions for Sig IQ-enabled customers. This is more than twice as many compared to 2023, which totaled 1.9 billion S&G Sigs returned.
  • Sig IQ augmented more than 2 million RxRenewal transactions in the first 6 months following its release in late 2023.

Surescripts Medication History with Sig IQ has made a significant and immediate impact on clinical review and continues to expand across the Surescripts Network Alliance alleviating potential patient harm.

“Since introducing Sig IQ capabilities for Medication History in 2022, we’ve expanded it to electronic prescribing transactions to truly enable this technology to deliver impact at scale, improving patient safety and overall efficiency across the Surescripts network,” said Frank Harvey, Chief Executive Officer for Surescripts. “Alleviating administrative tasks that slow down the prescribing process paired with prioritizing medication safety is how Surescripts innovations are easing the burdens facing prescribers and pharmacists. It’s a reminder that together, we’re going places and simpler, trusted health intelligence sharing takes us there.”

Surescripts Sig IQ technology addresses the uncertainty for clinicians and patients and additional administrative work that is often required to verify prescriber intent given that there are 832 ways to convey the most common patient medication direction of ‘take 1 tablet by mouth once daily.’ With 1.5 million emergency department visits each year stemming from adverse drug events, enabling standardized patient instructions for medications may help alleviate preventable instances of potential patient harm.

“From our roots in e-prescribing forward, Surescripts has been innovating on a massive, systemic scale for over two decades—helping patient information flow securely and seamlessly across the entire network,” said Tara Dragert, Chief Product Officer for Surescripts. “Our Sig IQ technology is another example of how we are always innovating to make an impact, improving patient safety by advancing electronic prescription accuracy while removing friction in the workflow and delivering a more complete view of the patient.”

Background:

Surescripts Sig IQ technology ensures that the free text patient instructions included by the prescriber, or Sig, are formatted and adhere to the NCPDP standards, using enhanced logic to identify opportunities to improve data quality or provide additional insights as the electronic prescribing transaction passes through the network.

This reduces potential transcription errors by allowing for the components of the Sig (such as route of administration) to be interpreted by every receiving system in the same way and helps alleviate administrative tasks that slow down the prescribing process.

For example, in ambulatory care, a structured and codified Sig field in an e-prescription can help clarify what a quantity of 30 caplets for a 30-day supply once daily really means – ensuring the prescriber’s intent is clear, whether the medication should be taken in the morning, night, with or without food, for a special indication or an off-label use.

Learn more about how we're leveraging Sig IQ to improve electronic prescribing and the medication reconciliation process for everyone involved.

About Surescripts

Our purpose is to serve the nation through simpler, trusted health intelligence sharing, in order to increase patient safety, lower costs and ensure quality care. At Surescripts, we align healthcare organizations across the nation and convene the Surescripts Network Alliance® to give healthcare professionals the trusted insights they need to serve patients. Together, we’re making interoperability an everyday reality, making it simpler to choose medications patients can afford and adhere to, and getting specialty medications to patients more efficiently. Visit us at surescripts.com and follow us on LinkedIn.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.